Paxlovid Soon Will Not Be Free for Americans
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — The antiviral Paxlovid has kept patients from becoming severely ill and dying from COVID-19 since it became available — at no cost to them. But by the middle of next year, the U.S. government will stop subs…
Learn MorePaxlovid Soon Won’t Be Free for Americans
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — The antiviral Paxlovid has kept people from getting really sick and dying from COVID-19 since it became available — at no cost to them. But by the middle of next year, the U.S. government will stop subsidiz…
Learn MoreSGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-relat…
Learn MoreDrug Choice Might Matter for Patients With Macular Degeneration
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests.Among 106 patients with “wet” age-related macular degeneration…
Learn MoreStudy Explores Impact of FDA Approval of Aducanumab on Trial Participation
TUESDAY, Dec. 6, 2022 (HealthDay News) — The U.S. Food and Drug Administration decision to approve aducanumab may have negatively impacted willingness to participate in preclinical Alzheimer disease (AD) trials, according to a study published online …
Learn MoreBromocriptine Quick Release Beneficial for Teens With T1DM
TUESDAY, Dec. 6, 2022 (HealthDay News) — For adolescents with type 1 diabetes (T1D), bromocriptine quick release (BCQR) improves blood pressure and central and peripheral aortic stiffness, according to a study published online Dec. 6 in Hypertension….
Learn MoreDapagliflozin Reduces Hospitalizations Among Patients With CKD
TUESDAY, Dec. 6, 2022 (HealthDay News) — For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.Meir Schechter, M.D., from th…
Learn MoreFDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants
MONDAY, Dec. 5, 2022 (HealthDay News) — The last of six COVID-19 monoclonal antibody treatments has lost its federal authorization because, like the others, it no longer works against the newest omicron subvariants.This last monoclonal antibody was b…
Learn MoreMore Biosimilars Marketed in Germany, Switzerland Than U.S.
FRIDAY, Dec. 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.D…
Learn MoreNo Significant Association Found for ADHD Meds, CVD Risk
FRIDAY, Dec. 2, 2022 (HealthDay News) — There seems to be no statistically significant association between attention-deficit/hyperactivity disorder (ADHD) medications and cardiovascular disease (CVD) risk, according to a systematic review and meta-an…
Learn More